Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

ICER Says Lecanemab Has Insufficient Net Health Benefit, “Low” Long-Term Value At Current Pricing; Post-Approval Evidence Will Be Key, But How?

March 20, 2023

“Conditional Approval” Redux? FDA Gives Advisory Committee “Two Scenarios” For Biogen/Ionis’ Tofersen In ALS: Accelerated Approval Or Full Approval

March 20, 2023

Prevision Policy Clips | CDER Office Of Compliance Annual Report

March 20, 2023

Biomarker Studies Proposed For Use In Labeling Require Subject-Level Data Submission, FDA Says In Revised PKG Guidance; “Voluntary” Program Ending

March 17, 2023

Opioid Overdose Treatments In Spotlight At FDA Workshop; Agency Hopes To Spread Message That Abstinence Is Not The Only Acceptable Endpoint

March 17, 2023

Paxlovid Endorsed For EUA-To-NDA Approval On Strength Of FDA Reassurances On Efficacy; DDIs Are Main Safety Concern

March 17, 2023

Prevision Policy Clips | Sarepta DMD Gene Therapy Will Go To Advisory Committee Ahead Of May 29 User Fee Deadline

March 17, 2023

CMS Casts Broad Net For Price Negotiation Targets: All NDAs With Same “Active Ingredient” Will Be Covered By “A Single Price”; Tight Timeline For Biosimilar Sponsors To Seek Delays

March 16, 2023

CMS Price Negotiation Benchmarks: Reference Pricing Tied To Therapeutic Alternatives Where Available, FSS Pricing Where Not; “Starting Point” Is Likely Key To Final Price

March 16, 2023

Prevision Policy Clips | CBER Gene Therapy “Super Office”: Witten’s Interim Director Role Likely To Run At Least Into Summer

March 16, 2023

Part B Inflation Rebate List Released By CMS: No Major Products Affected, First Year Collections May Not Reach $20 Million

March 15, 2023

Prevision Policy Clips | FDA Draft Guidance On Long-Acting Local Anesthetics Encourages Data Collection On Opioid Use

March 15, 2023

Pfizer Paxlovid NDA Conversion Complicated By Lack Of Efficacy In Vaccinated Populations; Approval Still Likely Heading To Panel Review

March 14, 2023

GAO Report Spotlights FDA Advanced Manufacturing Initiatives, Urges Agency To Flesh Out Metrics For ETP and FRAME

March 14, 2023

Prevision Policy Clips | Veterans Affairs Department To Cover Eisai/Biogen’s Leqembi For Alzheimer’s But Restricts Use To 65 And Older

March 14, 2023

Get Ready To DANCE: FDA/Duke RWE Negative Controls Meeting Features Two Projects, But Agency Says Activities Are Only At “The Start”

March 13, 2023

Prevision Policy Clips | GAO Advanced Manufacturing Report Spotlights FDA Efforts

March 13, 2023

FDA Proposes Emerging Pathogens Preparedness Program As PAHPA Add-On In Budget “Wish List”; LDTs Not Included In Requests To Congress

March 10, 2023

“Infected Trials,” Remote Inspection Guidances Among 18 CBER/CDER COVID Policies That Will Be Retained Post-Emergency; FDA Outlines Wind-Down Plan For Others

March 10, 2023

Genentech Polivy Wins Strong Support For First-Line DLBCL Claim Despite Skeptical FDA Review; ODAC Losing Streak Over

March 10, 2023

Prevision Policy Clips | FDA’s Gastrointestinal Drugs Advisory Committee To Review Intercept’s Ocaliva For NASH On May 19

March 10, 2023

HCV Subscription Model Is $11 Bil. Silver Lining For Drug Developers In White House Budget; Price Cuts Are Much Bigger Item, But Far Less Viable

March 10, 2023

Prevision Policy Clips | House Opioid Bill Would Require Manufacturers And Distributors To Report “Suspicious” Orders

March 9, 2023

Cell Therapy “Assessment Aid” Would Encourage Use Of Data Extrapolation For Next-Generation Oncology Indications; CBER Is Open To Idea

March 9, 2023

FDA Questions “Modest” Efficacy Of Genentech Polivy In First-Line DBCL Setting; Accelerated Approval Status For Refractory Disease Not At Issue For Panel Review

March 8, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy